Stapled Peptide Blocks Herpes Eye Infection by Targeting Viral DNA Machinery

A hydrocarbon-stapled peptide targeting HSV-1's processivity factor specifically blocked herpes DNA synthesis and infection in human corneal cells with a selectivity index of 11.6, offering a new approach for drug-resistant herpes keratitis.

Guan, Hancheng et al.·The ocular surface·2021·PreliminaryIn Vitro Study
RPEP-05420In Vitro StudyPreliminary2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
In Vitro Study
Evidence
Preliminary
Sample
N=N/A (in vitro)
Participants
Human primary corneal epithelial cells infected with HSV-1

What This Study Found

Optimized di-valine stapled peptide blocked HSV-1 DNA synthesis and infection in human primary corneal epithelial cells with selectivity index of 11.6. Unstapled control peptide had no effect. Peptide did not block unrelated virus infection (specificity confirmed).

Key Numbers

Selectivity index 11.6; di-valine optimization; specific to HSV-1; unstapled control had no effect

How They Did This

Structure-based peptide design from HSV-1 polymerase C-terminus crystal structure. Hydrocarbon stapling to maintain α-helical conformation. Testing of DNA synthesis inhibition, HSV-1 infection blocking, and specificity in human primary corneal epithelial cells.

Why This Research Matters

Acyclovir-resistant herpes is a growing clinical problem, especially for eye infections that can cause blindness. A peptide targeting a completely different viral protein provides a fallback treatment option.

The Bigger Picture

Stapled peptides are proving versatile across therapeutic areas. This application — blocking a viral enzyme's protein-protein interaction — demonstrates their potential in antiviral medicine, where protein interactions are often "undruggable" by conventional small molecules.

What This Study Doesn't Tell Us

In vitro study in human corneal cells only. Selectivity index of 11.6 is modest for drug development. Topical eye formulation, stability, and penetration not tested. In vivo efficacy in animal models of herpes keratitis not assessed.

Questions This Raises

  • ?Can the peptide be formulated as stable eye drops for clinical use?
  • ?Would this peptide work against acyclovir-resistant HSV-1 strains specifically?
  • ?Could similar stapled peptides target processivity factors of other herpesviruses?

Trust & Context

Key Stat:
Selectivity index 11.6 The optimized di-valine stapled peptide blocked HSV-1 infection in human corneal cells with meaningful selectivity — a foundation for topical herpes keratitis treatment
Evidence Grade:
Low evidence grade: in vitro proof-of-concept in human primary cells. No animal or clinical data. Selectivity index needs improvement for drug development.
Study Age:
Published 2021. Stapled peptide antivirals are a growing research area with increasing pharmaceutical interest.
Original Title:
Herpes Simplex Virus-1 infection in human primary corneal epithelial cells is blocked by a stapled peptide that targets processive DNA synthesis.
Published In:
The ocular surface, 19, 313-321 (2021)
Database ID:
RPEP-05420

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is herpes keratitis?

Herpes keratitis is an HSV-1 infection of the cornea (the clear front part of the eye). It is a leading cause of infectious blindness worldwide. Current treatment with acyclovir is effective but resistance is increasing.

Why use a stapled peptide instead of regular antiviral drugs?

Acyclovir works by targeting the viral thymidine kinase, but resistant viruses have mutations in this enzyme. The stapled peptide targets a completely different viral protein (the processivity factor), so it should work even against acyclovir-resistant strains.

Read More on RethinkPeptides

Cite This Study

RPEP-05420·https://rethinkpeptides.com/research/RPEP-05420

APA

Guan, Hancheng; Nuth, Manunya; Lee, Vivian; Lin, Chenyan; Mitchell, Claire H; Lu, Wennan; Scott, Richard W; Parker, Michael H; Kulp, John L; Reitz, Allen B; Ricciardi, Robert P. (2021). Herpes Simplex Virus-1 infection in human primary corneal epithelial cells is blocked by a stapled peptide that targets processive DNA synthesis.. The ocular surface, 19, 313-321. https://doi.org/10.1016/j.jtos.2020.11.001

MLA

Guan, Hancheng, et al. "Herpes Simplex Virus-1 infection in human primary corneal epithelial cells is blocked by a stapled peptide that targets processive DNA synthesis.." The ocular surface, 2021. https://doi.org/10.1016/j.jtos.2020.11.001

RethinkPeptides

RethinkPeptides Research Database. "Herpes Simplex Virus-1 infection in human primary corneal ep..." RPEP-05420. Retrieved from https://rethinkpeptides.com/research/guan-2021-herpes-simplex-virus1-infection

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.